TLRY vs. CRON, USNA, CGC, MNMD, BTMD, SNDL, ACB, CDXC, FOMX, and MDWD
Should you be buying Tilray stock or one of its competitors? The main competitors of Tilray include Cronos Group (CRON), USANA Health Sciences (USNA), Canopy Growth (CGC), Mind Medicine (MindMed) (MNMD), biote (BTMD), SNDL (SNDL), Aurora Cannabis (ACB), ChromaDex (CDXC), Menlo Therapeutics (FOMX), and MediWound (MDWD).
Tilray (NASDAQ:TLRY) and Cronos Group (NASDAQ:CRON) are both small-cap consumer staples companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, community ranking, valuation and risk.
In the previous week, Tilray had 4 more articles in the media than Cronos Group. MarketBeat recorded 9 mentions for Tilray and 5 mentions for Cronos Group. Cronos Group's average media sentiment score of 1.09 beat Tilray's score of 0.43 indicating that Cronos Group is being referred to more favorably in the news media.
Tilray has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
Cronos Group received 17 more outperform votes than Tilray when rated by MarketBeat users. Likewise, 61.13% of users gave Cronos Group an outperform vote while only 59.28% of users gave Tilray an outperform vote.
Tilray has a net margin of -43.98% compared to Cronos Group's net margin of -61.31%. Tilray's return on equity of -2.68% beat Cronos Group's return on equity.
Tilray presently has a consensus target price of $2.71, suggesting a potential upside of 53.01%. Cronos Group has a consensus target price of $3.00, suggesting a potential upside of 23.46%. Given Tilray's stronger consensus rating and higher possible upside, analysts plainly believe Tilray is more favorable than Cronos Group.
Cronos Group has lower revenue, but higher earnings than Tilray. Cronos Group is trading at a lower price-to-earnings ratio than Tilray, indicating that it is currently the more affordable of the two stocks.
9.4% of Tilray shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 0.7% of Tilray shares are held by insiders. Comparatively, 6.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Tilray beats Cronos Group on 11 of the 18 factors compared between the two stocks.
Get Tilray News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLRY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
